Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 627

1.

Induction of sustained remission in early inflammatory arthritis with the combination of infliximab plus methotrexate: the DINORA trial.

Stamm TA, Machold KP, Aletaha D, Alasti F, Lipsky P, Pisetsky D, Landewe R, van der Heijde D, Sepriano A, Aringer M, Boumpas D, Burmester G, Cutolo M, Ebner W, Graninger W, Huizinga T, Schett G, Schulze-Koops H, Tak PP, Martin-Mola E, Breedveld F, Smolen J.

Arthritis Res Ther. 2018 Aug 9;20(1):174. doi: 10.1186/s13075-018-1667-z.

2.

Long-term use of adalimumab as monotherapy after attainment of low disease activity with adalimumab plus methotrexate in patients with rheumatoid arthritis.

Keystone EC, Breedveld FC, Kupper H, Li Y, Florentinus S, Sainsbury I.

RMD Open. 2018 Jun 13;4(1):e000637. doi: 10.1136/rmdopen-2017-000637. eCollection 2018.

3.

Advances in targeted therapies 2017.

Breedveld FC, Kalden JR, Smolen JS.

Clin Immunol. 2018 Jan;186:1-2. doi: 10.1016/j.clim.2018.01.007. Epub 2018 Jan 31. No abstract available.

PMID:
29378299
4.

Achieving comprehensive disease control in patients with early and established rheumatoid arthritis treated with adalimumab plus methotrexate versus methotrexate alone.

Keystone EC, Breedveld FC, van der Heijde D, van Vollenhoven RF, Emery P, Smolen JS, Sainsbury I, Florentinus S, Kupper H, Chen K, Kavanaugh A.

RMD Open. 2017 Sep 26;3(2):e000445. doi: 10.1136/rmdopen-2017-000445. eCollection 2017.

5.

A Pilot Dose-Finding Study of Etanercept in Rheumatoid Arthritis.

Breedveld FC, Jones HE, Peifer K, Korth-Bradley J.

Clin Transl Sci. 2018 Jan;11(1):38-45. doi: 10.1111/cts.12502. Epub 2017 Sep 11.

6.

Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases.

Kay J, Schoels MM, Dörner T, Emery P, Kvien TK, Smolen JS, Breedveld FC; Task Force on the Use of Biosimilars to Treat Rheumatological Diseases.

Ann Rheum Dis. 2018 Feb;77(2):165-174. doi: 10.1136/annrheumdis-2017-211937. Epub 2017 Sep 2.

PMID:
28866648
7.

Advances in targeted therapy.

Breedveld FC, Kalden JR, Smolen JS.

Rheumatology (Oxford). 2016 Dec;55(suppl 2):ii1-ii2. No abstract available.

PMID:
27856653
8.

The unmet need in rheumatology: reports from the Targeted Therapies meeting 2016.

Winthrop KL, Strand V, van der Heijde DM, Mease PJ, Crow MK, Weinblatt M, Bathon JM, Buch MH, Burmester GR, Dougados M, Kay J, Mariette X, Breedveld FC, Kalden JR, Smolen JS, Furst DE.

Clin Exp Rheumatol. 2016 Jul-Aug;34(4 Suppl 98):69-76. Epub 2016 Aug 3.

9.

Clinical trials of new drugs for the treatment of rheumatoid arthritis: focus on early disease.

Smolen JS, Collaud Basset S, Boers M, Breedveld F, Edwards CJ, Kvien TK, Miossec P, Sokka-Isler T, van Vollenhoven RF, Abadie EC, Bruyère O, Cooper C, Mäkinen H, Thomas T, Tugwell P, Reginster JY; European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO).

Ann Rheum Dis. 2016 Jul;75(7):1268-71. doi: 10.1136/annrheumdis-2016-209429. Epub 2016 Apr 1. Review.

10.

Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update.

Stoffer MA, Schoels MM, Smolen JS, Aletaha D, Breedveld FC, Burmester G, Bykerk V, Dougados M, Emery P, Haraoui B, Gomez-Reino J, Kvien TK, Nash P, Navarro-Compán V, Scholte-Voshaar M, van Vollenhoven R, van der Heijde D, Stamm TA.

Ann Rheum Dis. 2016 Jan;75(1):16-22. doi: 10.1136/annrheumdis-2015-207526. Epub 2015 May 19. Review. Erratum in: Ann Rheum Dis. 2016 May;75(5):946.

11.

Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force.

Smolen JS, Breedveld FC, Burmester GR, Bykerk V, Dougados M, Emery P, Kvien TK, Navarro-Compán MV, Oliver S, Schoels M, Scholte-Voshaar M, Stamm T, Stoffer M, Takeuchi T, Aletaha D, Andreu JL, Aringer M, Bergman M, Betteridge N, Bijlsma H, Burkhardt H, Cardiel M, Combe B, Durez P, Fonseca JE, Gibofsky A, Gomez-Reino JJ, Graninger W, Hannonen P, Haraoui B, Kouloumas M, Landewe R, Martin-Mola E, Nash P, Ostergaard M, Östör A, Richards P, Sokka-Isler T, Thorne C, Tzioufas AG, van Vollenhoven R, de Wit M, van der Heijde D.

Ann Rheum Dis. 2016 Jan;75(1):3-15. doi: 10.1136/annrheumdis-2015-207524. Epub 2015 May 12. Review.

12.

TNF antagonists opened the way to personalized medicine in rheumatoid arthritis.

Breedveld F.

Mol Med. 2014 Dec 16;20 Suppl 1:S7-9. doi: 10.2119/molmed.2014.00168. Review.

13.

Longterm effect of delaying combination therapy with tumor necrosis factor inhibitor in patients with aggressive early rheumatoid arthritis: 10-year efficacy and safety of adalimumab from the randomized controlled PREMIER trial with open-label extension.

Keystone EC, Breedveld FC, van der Heijde D, Landewé R, Florentinus S, Arulmani U, Liu S, Kupper H, Kavanaugh A.

J Rheumatol. 2014 Jan;41(1):5-14. doi: 10.3899/jrheum.130543. Epub 2013 Nov 15.

14.

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update.

Smolen JS, Landewé R, Breedveld FC, Buch M, Burmester G, Dougados M, Emery P, Gaujoux-Viala C, Gossec L, Nam J, Ramiro S, Winthrop K, de Wit M, Aletaha D, Betteridge N, Bijlsma JW, Boers M, Buttgereit F, Combe B, Cutolo M, Damjanov N, Hazes JM, Kouloumas M, Kvien TK, Mariette X, Pavelka K, van Riel PL, Rubbert-Roth A, Scholte-Voshaar M, Scott DL, Sokka-Isler T, Wong JB, van der Heijde D.

Ann Rheum Dis. 2014 Mar;73(3):492-509. doi: 10.1136/annrheumdis-2013-204573. Epub 2013 Oct 25.

15.

Documentation of off-label use of biologics in Rheumatoid Arthritis.

Furst DE, Fleischman R, Kalden J, Kavanaugh A, Sieper J, Mease P, Smolen J, Breedveld F.

Ann Rheum Dis. 2013 Apr;72 Suppl 2:ii35-51. doi: 10.1136/annrheumdis-2013-consensusapp. Review. No abstract available.

PMID:
23532442
16.

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012.

Furst DE, Keystone EC, So AK, Braun J, Breedveld FC, Burmester GR, De Benedetti F, Dörner T, Emery P, Fleischmann R, Gibofsky A, Kalden JR, Kavanaugh A, Kirkham B, Mease P, Rubbert-Roth A, Sieper J, Singer NG, Smolen JS, Van Riel PL, Weisman MH, Winthrop KL.

Ann Rheum Dis. 2013 Apr;72 Suppl 2:ii2-34. doi: 10.1136/annrheumdis-2013-203348. No abstract available.

PMID:
23532441
17.

Advances in targeted therapies XIV.

Breedveld FC, Kalden JR, Smolen JS.

Ann Rheum Dis. 2013 Apr;72 Suppl 2:ii1. doi: 10.1136/annrheumdis-2012-202416. No abstract available.

PMID:
23532438
18.

Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions.

Smolen JS, Schoels MM, Nishimoto N, Breedveld FC, Burmester GR, Dougados M, Emery P, Ferraccioli G, Gabay C, Gibofsky A, Gomez-Reino JJ, Jones G, Kvien TK, Murakami M, Betteridge N, Bingham CO 3rd, Bykerk V, Choy EH, Combe B, Cutolo M, Graninger W, Lanas A, Martin-Mola E, Montecucco C, Ostergaard M, Pavelka K, Rubbert-Roth A, Sattar N, Scholte-Voshaar M, Tanaka Y, Trauner M, Valentini G, Winthrop KL, de Wit M, van der Heijde D.

Ann Rheum Dis. 2013 Apr;72(4):482-92. doi: 10.1136/annrheumdis-2012-202469. Epub 2012 Nov 21.

19.

Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement.

Schoels MM, van der Heijde D, Breedveld FC, Burmester GR, Dougados M, Emery P, Ferraccioli G, Gabay C, Gibofsky A, Gomez-Reino JJ, Jones G, Kvien TK, Murakami M, Nishimoto N, Smolen JS.

Ann Rheum Dis. 2013 Apr;72(4):583-9. doi: 10.1136/annrheumdis-2012-202470. Epub 2012 Nov 10. Review. Erratum in: Ann Rheum Dis. 2013 Jun;72(6):1110. Murikama, Miho M [corrected to Murakami, Miho].

20.

Advances in targeted therapies XIII.

Breedveld FC, Kalden JR, Smolen JS.

Ann Rheum Dis. 2012 Apr;71 Suppl 2:i1. doi: 10.1136/annrheumdis-2011-201013. No abstract available.

PMID:
22460135
21.

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011.

Furst DE, Keystone EC, Braun J, Breedveld FC, Burmester GR, De Benedetti F, Dörner T, Emery P, Fleischmann R, Gibofsky A, Kalden JR, Kavanaugh A, Kirkham B, Mease P, Sieper J, Singer NG, Smolen JS, Van Riel PL, Weisman MH, Winthrop K.

Ann Rheum Dis. 2012 Apr;71 Suppl 2:i2-45. doi: 10.1136/annrheumdis-2011-201036. No abstract available.

PMID:
22460137
22.

European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies.

Gossec L, Smolen JS, Gaujoux-Viala C, Ash Z, Marzo-Ortega H, van der Heijde D, FitzGerald O, Aletaha D, Balint P, Boumpas D, Braun J, Breedveld FC, Burmester G, Cañete JD, de Wit M, Dagfinrud H, de Vlam K, Dougados M, Helliwell P, Kavanaugh A, Kvien TK, Landewé R, Luger T, Maccarone M, McGonagle D, McHugh N, McInnes IB, Ritchlin C, Sieper J, Tak PP, Valesini G, Vencovsky J, Winthrop KL, Zink A, Emery P; European League Against Rheumatism.

Ann Rheum Dis. 2012 Jan;71(1):4-12. doi: 10.1136/annrheumdis-2011-200350. Epub 2011 Sep 27.

23.

Treating Rheumatoid Arthritis to Target: multinational recommendations assessment questionnaire.

Haraoui B, Smolen JS, Aletaha D, Breedveld FC, Burmester G, Codreanu C, Da Silva JP, de Wit M, Dougados M, Durez P, Emery P, Fonseca JE, Gibofsky A, Gomez-Reino J, Graninger W, Hamuryudan V, Jannaut Peña MJ, Kalden J, Kvien TK, Laurindo I, Martin-Mola E, Montecucco C, Santos Moreno P, Pavelka K, Poor G, Cardiel MH, Stanislawska-Biernat E, Takeuchi T, van der Heijde D; Treat to Target Taskforce.

Ann Rheum Dis. 2011 Nov;70(11):1999-2002. doi: 10.1136/ard.2011.154179. Epub 2011 Jul 29.

24.

Biomarkers and personalised medicine in rheumatoid arthritis: a proposal for interactions between academia, industry and regulatory bodies.

Miossec P, Verweij CL, Klareskog L, Pitzalis C, Barton A, Lekkerkerker F, Reiter S, Laslop A, Breedveld F, Abadie E, Flamion B, Dere W, Mpofu S, Goel N, Ethgen D, Mitlak B, Ormarsdóttir S, Rao R, Tsouderos Y, Reginster JY; Group for Respect of Ethics and Excellence in Science (GREES).

Ann Rheum Dis. 2011 Oct;70(10):1713-8. doi: 10.1136/ard.2011.154252. Epub 2011 Jul 22. Review.

25.

Understanding emerging treatment paradigms in rheumatoid arthritis.

Breedveld FC, Combe B.

Arthritis Res Ther. 2011 May 25;13 Suppl 1:S3. doi: 10.1186/1478-6354-13-S1-S3. Review.

26.

Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis.

Buch MH, Smolen JS, Betteridge N, Breedveld FC, Burmester G, Dörner T, Ferraccioli G, Gottenberg JE, Isaacs J, Kvien TK, Mariette X, Martin-Mola E, Pavelka K, Tak PP, van der Heijde D, van Vollenhoven RF, Emery P; Rituximab Consensus Expert Committee.

Ann Rheum Dis. 2011 Jun;70(6):909-20. doi: 10.1136/ard.2010.144998. Epub 2011 Mar 6.

27.

The value of early intervention in RA--a window of opportunity.

Breedveld F.

Clin Rheumatol. 2011 Mar;30 Suppl 1:S33-9. doi: 10.1007/s10067-010-1638-5. Epub 2011 Feb 25. Review.

PMID:
21350796
28.

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010.

Furst DE, Keystone EC, Braun J, Breedveld FC, Burmester GR, De Benedetti F, Dörner T, Emery P, Fleischmann R, Gibofsky A, Kalden JR, Kavanaugh A, Kirkham B, Mease P, Sieper J, Singer NG, Smolen JS, Van Riel PL, Weisman MH, Winthrop K.

Ann Rheum Dis. 2011 Mar;70 Suppl 1:i2-36. doi: 10.1136/ard.2010.146852. No abstract available.

PMID:
21339216
29.

Advances in targeted therapies XII. Preface.

Breedveld FC, Kalden JR, Smolen JS.

Ann Rheum Dis. 2011 Mar;70 Suppl 1:i1. doi: 10.1136/ard.2010.141044. No abstract available.

PMID:
21339210
30.

Updating the 2003 European regulatory requirements for registering disease-modifying drugs to be used in the treatment of rheumatoid arthritis.

Smolen JS, Boers M, Abadie EC, Breedveld FC, Emery P, Bardin T, Goel N, Ethgen DJ, Avouac BP, Durez P, Flamion B, Laslop A, Miossec P, Reiter S, Reginster JY; Task Force of the Group for the Respect of Ethics and Excellence in Science.

Rheumatology (Oxford). 2011 Oct;50(10):1732-6. doi: 10.1093/rheumatology/keq413. Epub 2011 Jan 17. No abstract available.

PMID:
21242246
31.

Recommendations for an update of 2003 European regulatory requirements for registration of drugs to be used in the treatment of RA.

Smolen JS, Boers M, Abadie EC, Breedveld FC, Emery P, Bardin T, Goel N, Ethgen DJ, Avouac BP, Dere WH, Durez P, Matucci-Cerinic M, Flamion B, Laslop A, Lekkerkerker FJ, Miossec P, Mitlak BH, Ormarsdóttir S, Paolozzi L, Rao R, Reiter S, Tsouderos Y, Reginster JY; Group for Respect of Ethics and Excellence in Science (GREES).

Curr Med Res Opin. 2011 Feb;27(2):315-25. doi: 10.1185/03007995.2010.542135. Epub 2010 Dec 9.

PMID:
21142618
32.

Disease activity, physical function, and radiographic progression after longterm therapy with adalimumab plus methotrexate: 5-year results of PREMIER.

van der Heijde D, Breedveld FC, Kavanaugh A, Keystone EC, Landewé R, Patra K, Pangan AL.

J Rheumatol. 2010 Nov;37(11):2237-46. doi: 10.3899/jrheum.100208. Epub 2010 Oct 1.

33.

The appropriate use of non-steroidal anti-inflammatory drugs in rheumatic disease: opinions of a multidisciplinary European expert panel.

Burmester G, Lanas A, Biasucci L, Hermann M, Lohmander S, Olivieri I, Scarpignato C, Smolen J, Hawkey C, Bajkowski A, Berenbaum F, Breedveld F, Dieleman P, Dougados M, MacDonald T, Mola EM, Mets T, Van den Noortgate N, Stoevelaar H.

Ann Rheum Dis. 2011 May;70(5):818-22. doi: 10.1136/ard.2010.128660. Epub 2010 Sep 10.

34.

Costs of rituximab maintenance treatment in patients with refractory rheumatoid arthritis.

Risselada A, Tekstra J, Teng YK, Welsing PM, Breedveld F, van Laar JM, Bijlsma JW.

Ann Rheum Dis. 2010 Oct;69(10):1891-2. doi: 10.1136/ard.2009.126029. Epub 2010 May 5. No abstract available.

PMID:
20444758
35.

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs.

Smolen JS, Landewé R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, Gorter S, Knevel R, Nam J, Schoels M, Aletaha D, Buch M, Gossec L, Huizinga T, Bijlsma JW, Burmester G, Combe B, Cutolo M, Gabay C, Gomez-Reino J, Kouloumas M, Kvien TK, Martin-Mola E, McInnes I, Pavelka K, van Riel P, Scholte M, Scott DL, Sokka T, Valesini G, van Vollenhoven R, Winthrop KL, Wong J, Zink A, van der Heijde D.

Ann Rheum Dis. 2010 Jun;69(6):964-75. doi: 10.1136/ard.2009.126532. Epub 2010 May 5. Review. Erratum in: Ann Rheum Dis. 2011 Aug;70(8):1519.

36.

Evidence for treating rheumatoid arthritis to target: results of a systematic literature search.

Schoels M, Knevel R, Aletaha D, Bijlsma JWJ, Breedveld FC, Boumpas DT, Burmester G, Combe B, Cutolo M, Dougados M, Emery P, van der Heijde D, Huizinga TWJ, Kalden J, Keystone EC, Kvien TK, Martin-Mola E, Montecucco C, de Wit M, Smolen JS.

Ann Rheum Dis. 2010 Apr;69(4):638-643. doi: 10.1136/ard.2009.123976. Review. Erratum in: Ann Rheum Dis. 2011 Aug;70(8):1519.

37.

The Stop Arthritis Very Early (SAVE) trial, an international multicentre, randomised, double-blind, placebo-controlled trial on glucocorticoids in very early arthritis.

Machold KP, Landewé R, Smolen JS, Stamm TA, van der Heijde DM, Verpoort KN, Brickmann K, Vázquez-Mellado J, Karateev DE, Breedveld FC, Emery P, Huizinga TW.

Ann Rheum Dis. 2010 Mar;69(3):495-502. doi: 10.1136/ard.2009.122473. Erratum in: Ann Rheum Dis. 2011 Aug;70(8):1519.

PMID:
20223838
38.

Treating rheumatoid arthritis to target: recommendations of an international task force.

Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester G, Combe B, Cutolo M, de Wit M, Dougados M, Emery P, Gibofsky A, Gomez-Reino JJ, Haraoui B, Kalden J, Keystone EC, Kvien TK, McInnes I, Martin-Mola E, Montecucco C, Schoels M, van der Heijde D; T2T Expert Committee.

Ann Rheum Dis. 2010 Apr;69(4):631-7. doi: 10.1136/ard.2009.123919. Epub 2010 Mar 9. Erratum in: Ann Rheum Dis. @011 Jul;70(7):1349. van der Heijde, Desirée [corrected to van der Heijde, Désirée]. Ann Rheum Dis. 2011 Aug;70(8):1519.

39.

Two-year clinical and radiographic results with combination etanercept-methotrexate therapy versus monotherapy in early rheumatoid arthritis: a two-year, double-blind, randomized study.

Emery P, Breedveld F, van der Heijde D, Ferraccioli G, Dougados M, Robertson D, Pedersen R, Koenig AS, Freundlich B; Combination of Methotrexate and Etanercept in Early Rheumatoid Arthritis Trial Group.

Arthritis Rheum. 2010 Mar;62(3):674-82. doi: 10.1002/art.27268. Erratum in: Arthritis Rheum. 2010 Oct;62(10):3005.

40.

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009.

Furst DE, Keystone EC, Fleischmann R, Mease P, Breedveld FC, Smolen JS, Kalden JR, Braun J, Bresnihan B, Burmester GR, De Benedetti F, Dörner T, Emery P, Gibofsky A, Kavanaugh A, Kirkham B, Schiff MH, Sieper J, Singer N, Van Riel PL, Weinblatt ME, Weisman MH, Winthrop K.

Ann Rheum Dis. 2010 Jan;69 Suppl 1:i2-29. doi: 10.1136/ard.2009.123885. No abstract available. Erratum in: Ann Rheum Dis. 2011 Aug;70(8):1519.

PMID:
19995740
41.

Advances in targeted therapies XI.

Breedveld FC, Kalden JR, Smolen JS.

Ann Rheum Dis. 2010 Jan;69 Suppl 1:i1. doi: 10.1136/ard.2009.120253. No abstract available.

PMID:
19995739
42.

Brain involvement in rheumatoid arthritis: a magnetic resonance spectroscopy study.

Emmer BJ, van der Bijl AE, Huizinga TW, Breedveld FC, Steens SC, Th Bosma GP, van Buchem MA, van der Grond J.

Arthritis Rheum. 2009 Nov;60(11):3190-5. doi: 10.1002/art.24932.

43.

Intranasal administration of recombinant human cartilage glycoprotein-39 as a treatment for rheumatoid arthritis: a phase II, multicentre, double-blind, randomised, placebo-controlled, parallel-group, dose-finding trial.

Landewé RB, Houbiers JG, Van den Bosch F, in't Hout J, Verschueren PC, Meijerink JH, van den Hoogen FH, Masek BA, Bruyn GA, Wouters JM, Voskuyl AE, van Laar JM, Bijlsma JJ, van der Heijde DM, Breedveld FC, van de Putte LB, Miltenburg AM, de Keyser F.

Ann Rheum Dis. 2010 Sep;69(9):1655-9. doi: 10.1136/ard.2009.117234. Epub 2009 Sep 23.

PMID:
19778914
44.

Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690,550, an orally active Janus kinase (JAK) inhibitor: results from a randomised, double-blind, placebo-controlled trial.

Coombs JH, Bloom BJ, Breedveld FC, Fletcher MP, Gruben D, Kremer JM, Burgos-Vargas R, Wilkinson B, Zerbini CA, Zwillich SH.

Ann Rheum Dis. 2010 Feb;69(2):413-6. doi: 10.1136/ard.2009.108159. Epub 2009 Jul 8.

PMID:
19587388
45.

Efficacy of intraarticular infliximab in patients with chronic or recurrent gonarthritis: a clinical randomized trial.

van der Bijl AE, Teng YK, van Oosterhout M, Breedveld FC, Allaart CF, Huizinga TW.

Arthritis Rheum. 2009 Jul 15;61(7):974-8. doi: 10.1002/art.24513.

46.

The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo.

Kremer JM, Bloom BJ, Breedveld FC, Coombs JH, Fletcher MP, Gruben D, Krishnaswami S, Burgos-Vargas R, Wilkinson B, Zerbini CA, Zwillich SH.

Arthritis Rheum. 2009 Jul;60(7):1895-905. doi: 10.1002/art.24567. Erratum in: Arthritis Rheum. 2012 May;64(5):1487.

47.

Rituximab fixed retreatment versus on-demand retreatment in refractory rheumatoid arthritis: comparison of two B cell depleting treatment strategies.

Teng YK, Tekstra J, Breedveld FC, Lafeber F, Bijlsma JW, van Laar JM.

Ann Rheum Dis. 2009 Jun;68(6):1075-7. doi: 10.1136/ard.2008.100438. No abstract available.

PMID:
19435725
48.

Rheumatoid arthritis joint progression in sustained remission is determined by disease activity levels preceding the period of radiographic assessment.

Aletaha D, Funovits J, Breedveld FC, Sharp J, Segurado O, Smolen JS.

Arthritis Rheum. 2009 May;60(5):1242-9. doi: 10.1002/art.24433.

49.

Follow-up standards and treatment targets in rheumatoid arthritis: results of a questionnaire at the EULAR 2008.

Schoels M, Aletaha D, Smolen JS, Bijlsma JW, Burmester G, Breedveld FC, Cutolo M, Combe B, Dougados M, Emery P, Kalden J, Keystone EC, Kvien TK, Martin-Mola E, Montecucco C, De Wit M.

Ann Rheum Dis. 2010 Mar;69(3):575-8. doi: 10.1136/ard.2009.108472. Epub 2009 Apr 22. Erratum in: Ann Rheum Dis. 2011 Aug;70(8):1519.

50.

Cost-utility analysis of treatment strategies in patients with recent-onset rheumatoid arthritis.

van den Hout WB, Goekoop-Ruiterman YP, Allaart CF, de Vries-Bouwstra JK, Hazes JM, Kerstens PJ, van Zeben D, Hulsmans HM, de Jonge-Bok JM, de Sonnaville PB, Dijkmans BA, Breedveld FC.

Arthritis Rheum. 2009 Mar 15;61(3):291-9. doi: 10.1002/art.24169.

Supplemental Content

Loading ...
Support Center